The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, multicenter, double-blind, placebo-controlled study of the Bruton tyrosine kinase inhibitor, ibrutinib, versus placebo in combination with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).
 
Margaret A. Tempero
Consulting or Advisory Role - AstraZeneca; Asuragen; Bayer; Celgene; Myriad Genetics; Nucana; Pfizer; Portola Pharmaceuticals; Roche/Genentech
 
Lisa M Coussens
Consulting or Advisory Role - AstraZeneca/MedImmune; Celgene; Five Prime Therapeutics; Pharmacyclics
Research Funding - Acerta Pharma; Deciphera; Janssen Research & Development
 
Lawrence Fong
No Relationships to Disclose
 
Robert Manges
No Relationships to Disclose
 
Priyanka Singh
Employment - Pharmacyclics
Stock and Other Ownership Interests - AbbVie
 
Yunfeng Li
Employment - Pharmacyclics
Stock and Other Ownership Interests - AbbVie
 
George W. Cole
Employment - Pharmacyclics
Stock and Other Ownership Interests - Pharmacyclics
 
Danelle Frances James
Employment - Pharmacyclics
Stock and Other Ownership Interests - AbbVie
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical